News & Insights Search

Industry stakeholders want the US Food and Drug Administration (FDA) to expand the scope of its recent draft guidance on the types of scientifically valid prior knowledge sponsors may consider when developing gene therapies that involve genome editing to explicitly apply to other types of cell and gene therapies (CGT).

The UK government has filed legal amendments intended to modernize the regulation of medicines and medical devices.

Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.

The European Medicines Agency (EMA) has launched a voluntary data submission (VDS) pilot to allow drug developers to share data generated by new approach methodologies (NAM), which regulators say may help reduce the need for traditional animal studies during drug development. The announcement follows other efforts by global regulators to reduce reliance on animal testing.

Sponsors who want to use digitally derived endpoints from digital health technologies (DHT) should validate those endpoints for the intended patient population, pre-specify their missing-data strategy at every level of their clinical trial, and avoid conflating device clearance with endpoint validation, according to US Food and Drug Administration (FDA) officials who spoke at a recent public meeting.

The US Food and Drug Administration (FDA) has published a draft guidance on how to design trials and analyze data from studies examining the pharmacokinetics (PK) and pharmacodynamics (PD) of drugs in patients with hepatic impairment (HI). The agency noted that impaired liver function can have a significant impact on how drugs are absorbed and filtered, requiring a better understanding of their effects.

Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.

The US Food and Drug Administration (FDA) could take additional steps to more successfully implement disclosures of complete response letters (CRLs) to the public, experts argued in a recent paper published in the Journal of Law and the Biosciences.

Industry and patient groups have asked the US Food and Drug Administration (FDA) to make several changes to its revised draft guidance on master protocols for drugs and biological products. Additionally, two industry groups pushed for greater harmonization with global regulators, while a group representing clinical trial sites questioned the practicality of the guidance when it comes to site-level operations.

The Indian government has simplified the regulatory framework for outsourced sterilization of medical devices as part of a push to support businesses.